(Q43848491)

English

Intraocular pressure over 24 hours after single-dose administration of latanoprost 0.005% in healthy volunteers. A randomized, double-masked, placebo controlled, cross-over single center study

scientific article published in December 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Intraocular pressure over 24 hours after single-dose administration of latanoprost 0.005% in healthy volunteers. A randomized, double-masked, placebo controlled, cross-over single center study (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Larsson LI

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

publication date

1 December 2001

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Acta Ophthalmologica

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

79

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

567-571

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790604.X

21 January 2018

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790604.X

21 January 2018

Latanoprost: experience of 2-year treatment in Scandinavia.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790604.X

21 January 2018

Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790604.X

21 January 2018

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790604.X

21 January 2018

The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790604.X

21 January 2018

Ambulatory blood pressure monitoring in glaucoma. The nocturnal dip.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790604.X

21 January 2018

Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790604.X

21 January 2018

Aqueous flow in open-angle glaucoma.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790604.X

21 January 2018

Acetazolamide but not timolol lowers aqueous humor flow in sleeping humans

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790604.X

21 January 2018

A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790604.X

21 January 2018

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790604.X

21 January 2018

Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790604.X

21 January 2018

24-hour (nyctohemeral) and sleep-related variations of intraocular pressure in healthy white individuals.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790604.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790604.X

7 January 2021

based on heuristic

inferred from DOI database lookup

The significance of the diurnal tension variations in normal and glaucomatous eyes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790604.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Diurnal variation of intraocular pressure and the overriding effects of sleep

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790604.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790604.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790604.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790604.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Individual variability in the diurnal intraocular pressure curve

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790604.X

7 January 2021

based on heuristic

inferred from DOI database lookup

The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790604.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1034/J.1600-0420.2001.790604.X

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43848491&oldid=2103857925"